Pfizer buybacks.
BuybackStocks tracks every share-repurchase filing Pfizer (PFE) submits to SEC EDGAR. Quarterly execution detail below comes from SEC XBRL filings.
Shares retired (last 4Q)117.0M
Latest data2024-12-31
Filings tracked0
Quarterly execution (SEC XBRL)
Per-quarter dollars paid for share repurchases and shares retired, sourced from XBRL data on SEC EDGAR.
| Period | Quarter end | USD paid | Shares | Avg price |
|---|---|---|---|---|
| 2024 FY | 2022-12-31 | $2.0B | 39.0M | $51.28 |
| 2023 Q3 | 2022-10-02 | $2.0B | — | — |
| 2023 Q2 | 2022-07-03 | $2.0B | — | — |
| 2023 Q1 | 2023-04-02 | — | — | — |
| 2023 FY | 2022-12-31 | $2.0B | 39.0M | $51.28 |
| 2022 Q3 | 2022-10-02 | $2.0B | — | — |
| 2022 FY | 2022-12-31 | $2.0B | 39.0M | $51.28 |
| 2021 FY | 2019-12-31 | — | 213.0M | — |
Recent buyback filings
Every Form 8-K authorization, 10-Q issuer-purchase table, and 10-K disclosure for Pfizer, sourced from SEC EDGAR and editorialized by BuybackStocks.
No editorialized buyback filings tracked yet for this ticker. New filings publish automatically when SEC EDGAR receives them. Historical execution data appears in the quarterly table above.
Related
See the wider context for this program: the Top 20 buybacks of 2026, our glossary of repurchase concepts, or all recent SEC filings we've covered.